Press Releases MoonLake Immunotherapeutics

Equities

MLTX

KY61559X1045

Market Closed - Nasdaq Other stock markets 20:59:46 04/06/2024 BST			5-day change	1st Jan Change
40.82 ^USD	-2.79%		-0.07%	-32.41%

05-07	MoonLake Immunotherapeutics Q1 Net Loss Widens	MT
05-07	MoonLake Immunotherapeutics Reports Earnings Results for the First Quarter Ended March 31, 2024	CI

Press Releases

Unlock all the news: Be the first to know and act before the market!

100% Free Registration

MoonLake Immunotherapeutics starts Phase 3 VELA program of the Nanobody® sonelokimab in patients with moderate-to-severe hidradenitis suppurativa	05-16	GL
MoonLake Immunotherapeutics Reports First Quarter 2024 Financial Results and Provides a Business Update	05-07	AQ
MoonLake Immunotherapeutics Inks Three-Year Technology Partnership With Komodo Health To Advance Research on Inflammatory Skin and Joint Conditions	04-10	BU
MoonLake Immunotherapeutics inks three-year technology partnership with Komodo Health to advance research on inflammatory skin and joint conditions	04-10	AQ
MoonLake announces significant improvements with Nanobody® sonelokimab over 24 weeks in active psoriatic arthritis (PsA) and other important updates at its R&D Day	03-10	AQ
MoonLake announces significant improvements with Nanobody® sonelokimab over 24 weeks in active psoriatic arthritis (PsA) and other important updates at its R&D Day	03-10	GL
MoonLake Immunotherapeutics to present MIRA trial data of Nanobody® sonelokimab in hidradenitis suppurativa as a late breaker at the AAD Annual Meeting 2024	03-04	GL
MoonLake Immunotherapeutics Reports Full Year 2023 Financial Results, Recent Business Highlights and Announces an R&D Day on March 10	02-29	GL
MoonLake Immunotherapeutics Announces Positive Feedback from both FDA and EMA on Regulatory Path for the Phase 3 Program of the Nanobody sonelokimab in Hidradenitis Suppurativa	02-27	AQ
MoonLake Immunotherapeutics Announces Positive Feedback from both FDA and EMA on Regulatory Path for the Phase 3 Program of the Nanobody® sonelokimab (SLK) in Hidradenitis Suppurativa (HS)	02-26	GL
MoonLake Immunotherapeutics Reports Third Quarter 2023 Financial Results and Provides a Business Update	11-14	GL
MoonLake Immunotherapeutics : ARGO Week 12 Results	11-06	PU
MoonLake Immunotherapeutics announces landmark Phase 2 results for Nanobody sonelokimab in active psoriatic arthritis	11-06	AQ
MoonLake Immunotherapeutics announces landmark Phase 2 results for Nanobody® sonelokimab in active psoriatic arthritis	11-05	AQ
MoonLake Immunotherapeutics announces landmark Phase 2 results for Nanobody® sonelokimab in active psoriatic arthritis	11-05	GL
MoonLake Immunotherapeutics announces the full dataset from its 24-week MIRA clinical trial, establishing the Nanobody sonelokimab as a highly promising and differentiated therapeutic solution for Hidradenitis Suppurativa	16/10/23	AQ
MoonLake Immunotherapeutics announces the full dataset from its 24-week MIRA clinical trial, establishing the Nanobody® sonelokimab as a highly promising and differentiated therapeutic solution for Hidradenitis Suppurativa	15/10/23	AQ
MoonLake Immunotherapeutics announces the full dataset from its 24-week MIRA clinical trial, establishing the Nanobody® sonelokimab as a highly promising and differentiated therapeutic solution for Hidradenitis Suppurativa	15/10/23	GL
MoonLake Immunotherapeutics presents positive 12-week data from the Phase 2 MIRA trial with Nanobody Sonelokimab for Hidradenitis Suppurativa at the European Academy of Dermatology and Venereology Congress	12/10/23	AQ
MoonLake Immunotherapeutics presents positive 12-week data from the Phase 2 MIRA trial with Nanobody® Sonelokimab for Hidradenitis Suppurativa at the European Academy of Dermatology and Venereology Congress	11/10/23	GL

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases MoonLake Immunotherapeutics

Equities

MLTX

KY61559X1045

Press Releases

Filters